NIH Archives
NIH-funded trial to determine if immunomodulation can improve brain and cardiovascular dysfunction in Long COVID
Feb. 22, 2024—Vanderbilt University Medical Center is working with scientists around the U.S. to launch the first Phase III, multicenter, placebo-controlled trial to determine the effect of immunomodulation on Long COVID.
A biomarker for early Type 2 diabetes
Feb. 1, 2024—Genetic analyses suggest that branched chain amino acids may be a sensitive biomarker of early or subclinical Type 2 diabetes and could be used to identify risk and implement preventive measures.
Data haul improves immunotherapy response prediction
Jan. 16, 2024—Vanderbilt biostatisticians have developed an immunotherapy response model that outperforms existing predictive models.
Team uses COVID-19 to test automated acute disease profiling
Jan. 2, 2024—An automated solution for creating phenotyping algorithms, PheNorm, worked well to identify symptomatic COVID-19 cases in electronic health records, suggesting that automation could speed high-throughput phenotyping of acute disease.
Glucose metabolism influences B cell function
Dec. 29, 2023—Glucose metabolism influences the qualities of activated, mature B cells — white blood cells that are required for antibody-mediated immune responses, Vanderbilt researchers discovered.
Study examines social factors and cardiovascular disease risk
Dec. 18, 2023—Eight social factors were among the top 15 markers of cardiovascular disease risk and could help guide community prevention efforts, according to a new study using machine learning algorithms.
Gut microbiota metabolite protects against obesity: study
Dec. 8, 2023—Vanderbilt researchers have discovered that beneficial bacteria in the small intestines produce a compound that protects against obesity.
You missed a few: a better way to count health care-associated influenza cases
Dec. 8, 2023—The traditional definition of health care-associated influenza leads to gross undercounting, a Vanderbilt study suggests.
Role of immunity in kidney injury hints at a potential therapy: study
Dec. 5, 2023—Targeting the cytokine IL-22 could be a new therapeutic approach to prevent kidney injury caused by drugs or toxins, Vanderbilt researchers have discovered.
Study links gene network and pancreatic beta cell defects to Type 2 diabetes
Dec. 4, 2023—A comprehensive study that integrates multiple analytic approaches has linked a regulatory gene network and functional defects in insulin-producing pancreatic beta cells to Type 2 diabetes.
Commensal gut bacterium protects from severe intestinal infection
Nov. 21, 2023— The commensal bacterium Turicibacter sanguinis could be used to protect against severe intestinal infections, Vanderbilt researchers discovered.
Nasty microbe H. pylori has Achilles’ heel
Nov. 16, 2023—Vanderbilt researchers found that an H. pylori enzyme is essential for colonization of the stomach, suggesting it as a promising therapeutic target for H. pylori infection.